Skip to main content

Table 4 Logistic regression model showing factors associated with clinically relevant fibrosis at baseline (N = 2419)

From: Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada

 APRI> 1.5 (clinically relevant fibrosis) at baseline
 Univariate AnalysisMultivariable Analysis
VariableOR95% CIWald pOR95% CIWald p
Hepatitis B
 HBV negative Reference  Reference 
 HBV positive3.182.10–4.84< 0.00013.081.99–4.78< 0.001
Hepatitis C
 HCV negative Reference  Reference 
 HCV positive4.773.43–6.63< 0.00014.553.26–6.35< 0.001
Baseline AIDS
 No ADI ever Reference    
 None before/at FARVDT1.490.74–2.980.44  
  ≥ 1 before/at FARVDT1.630.77–3.46    
 White Reference    
Birth sex
 Female Reference    
 BC Reference    
 ON0.470.32–0.68< 0.0001  
Years on ARV1.020.98–1.060.37   
Age at first ARV1.021.01–1.040.0031.021.00–1.040.01
PWID3.472.49–4.82< 0.0001  
Baseline HIV viral load (Log10 copies/mL)
  < 4 Reference  Reference 
  > 52.461.35–4.48 2.151.16–3.970.02
Baseline CD4 count (cells/mm3)
  > 500 Reference    
  ≤ 1002.761.32–5.77    
  1. FARVDT first naïve ARV date, MSM Men who have Sex with Men, PWID People Who Infect Drugs, BC British Colombia, ON Ontario, QC Quebec
  2. Variables considered in the multivariate model included: hepatitis B, hepatitis C, race, province, age at first ARV treatment, MSM, baseline HIV viral load, baseline CD4 count. Due to co-linearity with hepatitis C, PWID was not included in the final model